Redeye provides a research update following the Q1 report published by Lipum earlier today. While the report did not include any major surprises, we focus on the recent events surrounding the company. With a bolstered cash position following the recent rights issue, Lipum is set to initiate preparations for the upcoming phase II trials. We reiterate our valuation of Lipum with a base case of SEK15.

info@redeye.se (Redeye.se)

Redeye AB - Redeye.se